Study on the Prognostic Values of Dynactin Genes in Low-Grade Glioma. (23rd April 2021)

• Record Type: Journal Article
• Authors: Su, Xiaotao; Li, Haoyu; Chen, Shaohua; Qin, Chao
• Is Part Of: Technology in cancer research & treatment. Volume 20(2021)
• Publication Date: 2021-04-23
• Subjects: low-grade glioma -- dynactin protein -- biomarker -- mutation -- immune infiltration; Oncology -- Periodicals; Cancer -- Diagnosis -- Periodicals; Cancer -- Treatment -- Technological innovations -- Periodicals; 616.994
• DOI: 10.1177/15330338211010143
• Languages: English
• ISSNs: 1533-0346

Abstract

Objective: This present study aims to investigate the potential prognostic values of dynactin genes ( DCTN) for predicting the overall survival (OS) in low-grade glioma (LGG) patients. Methods: The DCTN mRNA expression data were downloaded from The Cancer Genome Atlas database containing 518 patients with LGG. The Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses for DCTN genes were performed by using Database for Annotation, Visualization, and Integrated Discovery platform, and their enrichment results were verified by using the Biological Networks Gene Ontology tool. Next, the correlations between DCTN genes and LGG were identified by Pearson correlation coefficient analysis. The OS was estimated by Kaplan-Meier survival analysis. The cBio Cancer Genomics Portal was used to analyze the mutations of DCTN genes and their effects on the prognosis of LGG. The correlation between the abundance of immune infiltration and tumor purity of DCTN genes were predicted by The Tumor Immune Estimation Resource. Results: Our research showed that the mRNA expression of DCTN4 in tumor tissues was much higher ( P < 0.01) than that in normal tissues. Meanwhile, there was a certain correlation between the DCTN genes. Survival analysis showed that the high expression of DCTN1, DCTN3, DCTN4, DCTN6, and their co-expression were significantly correlated with favorable OS in LGG patients ( P < 0.05). In DCTN2, a high mutation rate was observed. Further research showed that the genetic alteration in DCTN genes was related to a poor OS and progression-free survival of LGG patients. The expression of DCTN genes had a certain correlation with immune infiltrating cells. Conclusion: Our study showed that the high expressions of DCTN1, DCTN3, DCTN4, and DCTN6 were associated with a favorable OS of LGG patients, indicating that these DCTN genes are potential biomarkers for evaluating the prognosis of LGG patients.